Andrew Witty jumped into biotech venture capital, Aerie poached another exec from Alcon, Roivant tapped Silicon Valley vet to run trial AI company.

In this week's EuroBiotech Report, phase 3 data send Bavarian Nordic and Nabriva in opposite directions, Immunocore raises $40 million and more. 

In our EuroBiotech roundup this week, Autolus advances CAR-T trial, Cell Medica names CSO and AB Science suffers a regulatory setback.

The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.

The startup has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million to take a LANCL2-targeted IBD drug into the clinic.

Researchers at Duke University developing a glioblastoma treatment based on poliovirus are unraveling the process by which the virus fights malignancy.

Researchers at Sanofi and the NIH have published preclinical evidence showing that a three-pronged approach may prevent HIV in healthy people.

VC Lightstone has $250 million in the bank for life science research.

Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.